TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

Posted by on Apr 23rd, 2025

Research analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research note issued on Wednesday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Trading Up 11.4 %

NASDAQ TXMD opened at $1.11 on Wednesday. TherapeuticsMD has a twelve month low of $0.70 and a twelve month high of $2.44. The stock has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.16.

TherapeuticsMD Company Profile

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.

Featured Stories

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.